Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KIDS
KIDS logo

KIDS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy OrthoPediatrics Corp (KIDS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
18.430
1 Day change
-0.38%
52 Week Range
23.700
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

KIDS is not a clear buy right now for a Beginner long-term investor, even with $50,000-$100,000 available. The stock has some constructive support from hedge fund buying and a few bullish analyst targets, but the current setup is mixed: pre-market price is 17.9, technicals are only modestly positive, recent analyst sentiment is split between Buy and Hold, and there is no fresh news catalyst. My direct view is to hold off rather than buy aggressively today.

Technical Analysis

The technical picture is mixed to slightly positive. MACD histogram is above zero at 0.23, which supports short-term momentum, but it is positively contracting, suggesting momentum is not accelerating. RSI_6 at 70.532 is near overbought territory despite being labeled neutral in the dataset, so upside extension looks limited near term. Moving averages are converging, which typically signals a lack of strong trend direction. Price at 17.9 is below R1 at 18.28 but above the pivot at 16.748, so the stock is sitting in the middle of the current range rather than in a decisive breakout zone.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on the surface, with an extremely low open interest put-call ratio of 0.02 and zero put volume ratio, indicating very little bearish positioning. However, total options activity is thin today with only 2 contracts traded and low volume in absolute terms, so the signal is supportive but not very strong. Implied volatility is elevated at 112.98, which suggests the market expects meaningful movement, but that does not by itself confirm a buy for a beginner long-term investor.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
8

Positive Catalysts

  • ["Hedge funds are buying, with buying amount up 114.29% over the last quarter.", "Canaccord raised its price target to $25 and keeps a Buy rating.", "BTIG raised its price target to $24 and keeps a Buy rating.", "Stifel raised its price target to $22 and keeps a Buy rating.", "Company is described as benefiting from new product launches and an NPL supercycle.", "Outside-U.S. business was noted as strong geographically."]

Neutral/Negative Catalysts

  • ["Truist lowered its price target to $17 from $20 and keeps a Hold rating.", "Recent analyst views are split, with more cautious Hold commentary still present.", "No news in the recent week, so there is no fresh catalyst driving the stock.", "Insiders are neutral with no significant recent trading trend.", "No congress trading data is available.", "The stock trend model suggests weak near-term performance, including an 80% chance of -0.29% next day and only 19.44% probability over the next month."]

Financial Performance

No reliable latest-quarter financial snapshot was available because the provided financial data returned an error. From the analyst commentary, the company appears to be progressing toward profitability with solid Q4 EBITDA and free cash flow generation, and Canaccord expects FCF breakeven in FY26. That suggests improving growth quality, but the exact latest-quarter season and hard revenue/profit numbers were not provided.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst sentiment is mixed but somewhat constructive. Bullish firms include Canaccord, BTIG, and Stifel, all with Buy ratings and higher price targets in the $22-$25 range. The main bearish change was Truist cutting its target to $17 and keeping Hold, which likely reflects multiple compression rather than a major business deterioration. Overall, Wall Street’s pros see long-term upside from product launches and profitability progress, while the cautious camp sees valuation and multiple pressure limiting near-term upside.

Wall Street analysts forecast KIDS stock price to rise
5 Analyst Rating
Wall Street analysts forecast KIDS stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.430
sliders
Low
20
Averages
23
High
26
Current: 18.430
sliders
Low
20
Averages
23
High
26
Truist
Hold
downgrade
$20 -> $17
AI Analysis
2026-05-01
Reason
Truist
Price Target
$20 -> $17
AI Analysis
2026-05-01
downgrade
Hold
Reason
Truist lowered the firm's price target on OrthoPediatrics to $17 from $20 and keeps a Hold rating on the shares. The firm notes that sales upside relative to consensus was balanced across product segments and outside-U.S. business was strong geographically, but its price target on the stock is cut to reflect the recent group multiple compression, the analyst tells investors in a research note.
Canaccord
Buy
maintain
$24 -> $25
2026-04-24
Reason
Canaccord
Price Target
$24 -> $25
2026-04-24
maintain
Buy
Reason
Canaccord raised the firm's price target on OrthoPediatrics to $25 from $24 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results. They continue to like the shares which is at the beginning of an NPL supercycle. The company executed on a beat in the Q4 while maintaining its conservative approach to guidance leaving out more variable elements which, if they improve, provide upside, while setting a baseline from which the company can profitably grow, evidenced by expectations for FCF breakeven in FY26.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KIDS
Unlock Now

People Also Watch